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fBACKGROUND & AIMS: Drug-induced liver injury
(DILI), especially from antimicrobial agents, is an impor-
tant cause of serious liver disease. Amoxicillin-clavulanate
(AC) is a leading cause of idiosyncratic DILI, but little is
understood about genetic susceptibility to this adverse
reaction. METHODS: We performed a genome-wide as-
sociation study using 822,927 single nucleotide polymor-
phism (SNP) markers from 201 White European and US
cases of DILI following AC administration (AC-DILI) and
532 population controls, matched for genetic back-
ground. RESULTS: AC-DILI was associated with many loci
in the major histocompatibility complex. The strongest ef-
fect was with an HLA class II SNP (rs9274407, P  4.8 
1014), which correlated with rs3135388, a tag SNP of HLA-
DRB1*1501-DQB1*0602 that was previously associated with
AC-DILI. Conditioned on rs3135388, rs9274407 is still sig-
nificant (P  1.1  104). An independent association was
bserved in the class I region (rs2523822, P  1.8  1010),
elated to HLA-A*0201. The most significant class I and II
NPs showed statistical interaction (P  .0015). High-reso-
ution HLA genotyping (177 cases and 219 controls) con-
rmed associations of HLA-A*0201 (P  2  106) and
LA-DQB1*0602 (P 5 1010) and their interaction (P
.005). Additional, population-dependent effects were ob-
served in HLA alleles with nominal significance. In an analy-
sis of autoimmune-related genes, rs2476601 in the gene
PTPN22 was associated (P 1.3 104). CONCLUSIONS:
Class I and II HLA genotypes affect susceptibility to
AC-DILI, indicating the importance of the adaptive im-
mune response in pathogenesis. The HLA genotypes
identified will be useful in studies of the pathogenesis of
AC-DILI but have limited utility as predictive or diag-
nostic biomarkers because of the low positive predictive
values.Keywords: Hepatotoxicity; Genome-Wide Association
Study; GWAS; Pharmacogenomics.
Idiosyncratic liver toxicity because of a prescribed drugis usually referred to as drug-induced liver injury
DILI). Most DILI involves reactions that appear unre-
ated to drug dose or concentration. Although compara-
ively rare, DILI is a serious clinical problem with up to
0% of cases with simultaneous severe elevations in ala-
ine transaminase (ALT) and bilirubin developing liver
ailure.1 A prospective study estimated the standardized
incidence rate of symptomatic hepatic adverse drug reac-
tions at 8.1 per 100,000 people in France.2 In the United
States, 13% of acute liver failure cases are because of
idiosyncratic hepatotoxicity with 75% of those dying or
requiring emergency liver transplantation.3
Amoxicillin-clavulanate (AC) is among the most com-
monly prescribed antimicrobials worldwide. This drug is
generally well tolerated, and, whereas liver injury can oc-
cur rarely, the overall risk benefit is favorable. DILI fol-
lowing AC administration (AC-DILI), which appears to be
Abbreviations used in this paper: AC, amoxicillin-clavulanate; AC-DILI,
DILI following AC administration; ADME, drug absorption, distribution,
metabolism, and excretion; ALP, alkaline phosphatase; ALT, alanine
transaminase; AST, aspartate aminotransferase; CI, conﬁdence inter-
val; CIOMS, Council for International Organizations of Medical Science;
DILI, drug-induced liver injury; DILIN, drug-induced liver injury network;
LD, linkage disequilibrium; MHC, major histocompatibility complex;
NPV, negative predictive value; OR, odds ratio; PBC, primary biliary
cirrhosis; POPRES, Population Reference Sample; Q-Q, quantile-quan-
tile; SNP, single nucleotide polymorphism; ULN, upper limit of normal.
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0016-5085/$36.00doi:10.1053/j.gastro.2011.04.001
hi
u
w
p
U
t
b
h
o
c
m
r
s
o
i
s
c
fi
B
A
SI
C
A
N
D
TR
A
N
SL
A
TI
O
N
A
L
LI
V
ER
July 2011 HLA AND AMOXICILLIN-CLAVULANATE TOXICITY 339primarily due to the clavulanate component,4 is an im-
portant cause of idiosyncratic DILI in the United States
and Europe,5–7 and represents 17% of all DILI-related
ospitalizations.6,8 Whereas most patients with AC-DILI
make a full recovery,5,9 cases of acute liver failure leading
to death or liver transplantation have been reported.10
The mechanism of AC-DILI is unknown. Three previous
studies from Northwestern Europe11–13 reported an asso-
ciation between AC-DILI and the HLA class II allele
DRB1*1501, with odds ratios (OR) ranging between 2.6
and 10. A further study of 27 Spanish cases did not
observe a significant association with DRB1*15 but did
report a significantly higher frequency of DQB1*06.14 The
differences in findings between the Spanish and North-
western European studies may be due to use of low-
resolution genotyping, population-specific linkage-dis-
equilibrium patterns, population stratification, or to a
larger proportion of hepatocellular cases in the Spanish
study.15
We conducted a genome-wide association (GWA) study
to investigate whether additional common genetic vari-
ants affect susceptibility to AC-DILI. A group of well-
phenotyped cases (n  201) with high causality scores
were assembled from several multicenter collections to-
gether with 532 genetically matched population controls.
Our study confirms the DRB1*1501 association and iden-
tifies additional HLA class I and II associations.
Materials and Methods
Case Recruitment
Cases (n  211) were recruited in 4 separate stud-
es (DILIGEN,16 Spanish DILI Registry,6 Drug-induced
liver injury network [DILIN],7 and EUDRAGENE17) that
sed similar inclusion criteria. All participants provided
ritten informed consent, and each study had been ap-
roved by the appropriate ethical review boards.
DILIGEN. Between October 2004 and April 2009,
78 cases of AC-DILI of European origin from centers
throughout the United Kingdom were collected. Inclusion
criteria were suspected liver injury because of AC with
either (1) clinically apparent jaundice or bilirubin 2.4
mg/dL (after exclusion of cases because of hemolysis), (2)
ALT 5X upper limit of normal (ULN), or (3) alkaline
phosphatase (ALP) 2X ULN plus bilirubin above ULN.
Cases were identified by searching histologic databases
and discharge records at UK regional liver units for cases
of DILI or cholestasis/hepatitis of unknown etiology. Di-
rect contact with gastroenterologists was also made by
advertising the study through professional societies.
EUDRAGENE. Adult (18 years of age) AC-DILI
cases identified retrospectively and prospectively from Eu-
ropean pharmacovigilance center adverse drug reaction
reports were collected from November 2006 to August
2009. Of the 25 cases included in this study, 15 were from
Spain, 7 from France, and 3 from Italy.
Case definitions included (1) acute liver injury defined
as presenting symptoms suggestive of liver disorder (nau- gsea, vomiting, abdominal pain, and/or jaundice), referred
to a specialist, or admitted to hospital; (2) ALT2X ULN;
or (3) aspartate aminotransferase (AST), ALP, and total
bilirubin 2X ULN.
Spanish DILI registry. Fifty-two cases of AC-DILI
patients 18 years of age were selected from those sub-
mitted to the Spanish DILI Registry, a collaborative net-
work set up in 1994 to prospectively identify cases of DILI
in a standardized manner. Inclusion laboratory criteria for
AC-DILI cases in this study were (1) clinically apparent
jaundice or bilirubin 2.4 mg/dL (after exclusion of cases
because of hemolysis), (2) ALT5X ULN, or (3) ALP2X
LN. Detailed description of the operational structure of
he registry, data recording, and case ascertainment has
een reported elsewhere.6
DILIN. Details of the DILIN prospective study
ave been described previously.18 A total of 65 eligible
AC-DILI cases was recruited between August 2004 and
April 2009 from 5 DILIN clinical sites in the United
States. Of these, 56 cases of European ancestry and 18
years of age were included in the current study. Inclusion
laboratory criteria were (1) serum AST or ALT 5X ULN
n 2 separate occasions, (2) serum ALP 2X ULN on 2
onsecutive occasions, or (3) serum total bilirubin 2.4
g/dL in the absence of a competing cause of hyperbili-
ubinemia. Patients were excluded if there was known or
uspected acetaminophen overdose, if there was a history
f bone marrow or liver transplant prior to DILI onset, or
f there was a prior history of immune-related liver disease
uch as autoimmune hepatitis.
Causality Assessment
Diagnosis of DILI was done by expert hepatolo-
gists at each of the collaborating centers. In addition, the
cases were evaluated by application of the Council for
International Organizations of Medical Science (CIOMS)
scale, also called the Roussel Uclaf Causality Assessment
Method (RUCAM). The pattern of liver injury was classified
according to the International Consensus Meeting Crite-
ria.19 Only cases having at least possible causality (score
3) were included in the study.
DNA Preparation From Cases
For DILIGEN and Spanish DILI Registry cases,
DNA was prepared as described previously.14,16 EU-
DRAGENE DNA was extracted at Erasmus Medical Cen-
tre genotyping laboratory, The Netherlands, using stan-
dard procedures. DILIN DNA was extracted from
lymphocytes and stored at the National Institute of Dia-
betes and Digestive and Kidney Diseases biosample repos-
itory at Rutgers University, Piscataway, NJ.
Controls
Genotyped controls (n  532) from the Popula-
tion Reference Sample (POPRES)20 were matched to the
ases using principal component analysis. Based on the
rst 2 principal components that capture much of the
enetic substructure among Europeans, 306 controls were
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340 LUCENA ET AL GASTROENTEROLOGY Vol. 141, No. 1selected as Northwestern Europeans (predominantly
POPRES UK), and 160 controls were selected as Spanish
(predominantly POPRES Spanish and Portuguese).
Genotyping
Genome-wide analysis. Genome-wide genotyping
of the European DILI cases and POPRES controls was
performed by Expression Analysis, Inc (Durham, NC) and
of the US cases by the Center for Human Genome Vari-
ation, Duke University. All subjects were genotyped using
the Human1M-Duo BeadChip (Illumina, San Diego, CA),
containing 1,072,820 markers. A total of 822,927 markers,
201 cases (77 DILIGEN, 19 EUDRAGENE, 49 Spanish
DILI Registry, and 56 DILIN) and 532 controls passed
quality control (see Supplementary Materials and
Methods).
HLA genotyping. High-resolution genotyping of
LA-A, -B, -DRB1, -DQA1, and -DQB1 was performed on a
ubset of genotyped subjects, including 182 cases (74
ILIGEN, 49 Spanish DILI Registry, and 59 DILIN) and
19 POPRES controls (genetically matched to cases as
escribed above) by Histogenetics (Ossining, New York) as
escribed in the Supplementary Materials and Methods.
Statistical Analysis
The statistical association of each marker in the
GWA study was determined by logistic regression with gen-
der and first 2 principal components as covariates under an
additive model and Fisher exact allelic test within subpopu-
lation analyses. GWA analyses were carried out with
Table 1. Clinical Characteristics of AC-DILI Cases
Cohorts DILIGEN EUDRAGENE
No. 77 19
Sex, n (%)
M 39 (51) 11 (58)
F 38 (49) 8 (42)
ge, y
Mean ( SD) 61 (14) 68 (14)
otal days on drug
Mean ( SD) 8 (6) 7 (5)
ays to DILI onset
Mean ( SD) 15 (14) 11 (9)
attern of liver injury, n (%)
Cholestatic 36 (47) 6 (32)
Mixed 18 (23) 5 (26)
Hepatocellular 19 (25) 0
Unknown 4 (5) 8 (42)
ausality (CIOMS), n (%)
Unlikely 0 0
Possible 7 (9) 1 (5)
Probable 25 (32) 12 (63)
Highly probable 45 (58) 6 (32)
eak Bilirubin, mg/dL
Mean ( SD) 12.5 (9.8) 10.8 (12.2)
eak ALT, U/L
Mean ( SD) 455 (465) 342 (268)
eak ALP, U/L
Mean ( SD) 453 (253) 438 (171)
, female; M, male; SD, standard deviation.PLINK.21 We inferred the genomic inflation factor by con-erting P values from regression test to 2 values then taking
the median (0.4687) divided by the expected median value
(0.456) of 2 distribution with 1 degree of freedom.
HLA haplotypes were inferred using Beagle version 2.1.22
Associations of HLA alleles were tested using logistic regres-
sion, including the first 2 principal component scores as
covariates to control for population stratification. To test for
independent effects within regions having multiple associ-
ated variants, we included 1 or more variants as a covariate
and tested the significance of other variants by adding them
stepwise. All detailed analyses were performed with R.23 Ad-
itional statistical analyses of HLA alleles were conducted by
ogistic regression using glm function (generalized linear
odel) and heterogeneity testing with meta.MH function
Mantel–Haenszel meta-analysis) from the rmeta package
http://cran.r-project.org/web/packages/rmeta/index.html) ad-
usting for gender and principal components when feasible.
Results
Clinical Characteristics of the Cases
Clinical details of the 201 cases included in this
study are summarized in Table 1. As in previous studies of
AC-DILI, there were more male than female cases. The
average age at onset was 61  14 years. Four cases under-
went liver transplantation. Most cases (70%) were charac-
terized as cholestatic or mixed at presentation, and 88%
had bilirubin levels 2.4 mg/dL. Most causality scores
(93%) suggested that DILI was either probably or highly
likely because of AC. There were some significant differ-
Spanish DILI Registry DILIN All
49 56 201
27 (55) 36 (64) 113 (56)
22 (45) 20 (36) 88 (44)
60 (18) 59 (14) 61 (14)
11 (9) 12 (8) 10 (7)
16 (12) 32 (19) 20 (17)
17 (35) 20 (36) 79 (39)
17 (35) 23 (41) 63 (31)
15 (31) 10 (18) 44 (22)
0 3 (5) 15 (7)
0 0 0
0 6 (11) 14 (7)
23 (47) 37 (66) 97 (48)
26 (53) 13 (23) 90 (45)
12.3 (9.5) 16.5 (11.8) 13.5 (10.6)
548 (668) 575 (713) 500 (584)
417 (286) 456 (293) 444 (268)ences in the pattern of disease and other phenotypic
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July 2011 HLA AND AMOXICILLIN-CLAVULANATE TOXICITY 341characteristics among the 4 collections (Supplementary
Table 1).
Genome-Wide Analysis
GWA analysis was carried out on 201 DILI cases
and 532 controls for 822,927 markers that passed quality
control. Principal component analysis showed that all
cases clustered within Northwestern, Western, and South-
ern Europe (Supplementary Figure 1), consistent with
previous studies on Europeans.24 Based on these genetic
atterns, the US-derived DILIN samples were predomi-
antly of Northwestern European origin with genotype
atterns correlating well with both UK controls and cases.
he genomic inflation factor () of our study was 1.03,
which indicates no problems with population stratifica-
tion.
Case-control association analysis revealed 1 marked
peak of association with several dozen genome-wide sig-
nificant SNPs within the major histocompatibility com-
plex (MHC) on chromosome 6p21.3 (Figure 1A). Quan-
tile-quantile (Q-Q) plots (Supplementary Figure 2)
suggested that no SNPs outside the MHC region showed
a genome-wide significant association with DILI. The
most significant associations localized within the class II
and class I regions (Figure 1B). The top SNP associated
with AC-DILI was rs9274407 (P  4.8  1014 with an
stimated additive OR of 3.1 (95% confidence interval
CI]: 2.3–4.2); Table 2). This SNP is located within the
LA-DQB1 gene and had relatively high linkage disequi-
ibrium (LD) (r2  0.76) with rs3135388, one of the other
top associated SNPs that is strongly correlated with (ie, a
tag for) DRB1*1501 and the haplotype DRB1*1501-
DQB1*0602.25 The top SNP (rs9274407) was significantly
ssociated conditioned on the tag SNP (rs3135388) (P 
00011), whereas rs3135388 was not significantly condi-
ioned on rs9274407 (P  .93).
Several SNPs from the HLA class I region were also
enome-wide significant, the most significant being
s2523822 (P  1.8  1010, OR, 2.3; 95% CI: 1.8–2.9),
reviously reported as a tag for A*0201.25 Conditioning
n rs9274407, the association peak within class I re-
ained genome-wide significant, whereas none of the
ther class II region SNPs remained significantly associ-
ted (Figure 1C, Supplementary Figure 2, Table 2). We
ound a statistically significant interaction (P  .0015,
R, 2.3; 95% CI: 1.4–3.8) between rs9274407 and
s2523822, indicating that the increased risk when both
inor alleles were present was larger than expected based
n their individual effects. Conditioned on both
s9274407 and rs2523822, no additional remarkable as-
ociations within the MHC were observed (Figure 2D).
A total of 14 of the 201 cases in the study had shown
possible” rather than “probable” or “highly probable”
ausality when scored by the CIOMS system.19 To assess
hether exclusion of these cases from the analysis would
ffect the overall findings, we recalculated P values for the
SNPs with the lowest P values (Table 2). No significant
lteration in these P values was seen (data not shown). tTo consider the potential for country-specific effects,
enome-wide analyses were carried out on 3 separate sub-
roups within the original 201 cases, namely 74 UK, 51
S cases with Northwestern European genetic back-
rounds, and 46 Spanish DILI Registry cases with Spanish
enetic background (Supplementary Figure 2). Appropri-
tely matched POPRES controls (306 Northwestern Eu-
opean for the United Kingdom and United States and
60 Spanish and Portuguese) were used. As with the
ombined samples, no SNPs outside the MHC were ge-
ome-wide significant, and most significant SNPs in the
ombined sample showed similar estimates of effects
ithin each of the 3 groups (Table 3). Conditioning anal-
sis on top SNPs, similar to that performed for the entire
roup shown in Table 2, was also performed on the
ifferent groups (Table 3). The association of rs9274407
onditioned on rs3135388 was observed only in the UK
roup with statistical significance (P  7.3  105).
Rs3135388 was not significantly associated conditioned
on rs9274407 consistently in all 3 groups, but rs2523822
was significantly associated conditioned on either
rs9274407 or rs3135388 in all 3 groups. The interaction
between the class I rs252382 and class II rs9274407, which
was significant for the entire group, was also significant in
the UK cases alone (P  .013) but not in the US and
Spanish cases (P  .14 and P  .31, respectively).
Although the Q-Q plots (Supplementary Figure 3) sug-
gested that no SNPs outside the MHC region were signif-
icantly associated with AC-DILI genome wide, we also
assessed whether there was any indication of a contribu-
tion from either genes concerned with drug absorption,
distribution, metabolism and excretion (ADME)26 or, in
iew of the strong HLA associations, non-HLA genes
nown to be involved in autoimmune diseases generally.27
We extracted all SNPs within 10 kilobase for a list of 130
ADME genes.26 A total of 4961 such SNPs were included
n our analysis. Figure 2A shows the Q-Q plot of P values
for these SNPs and indicates that no significant associa-
tions occur. For the autoimmune disease genes, we ex-
tracted SNPs associated with these diseases with reported
P value smaller than 5  108 (see Figure 2B).27 Among
these SNPs (213 in total), 158 had been genotyped and
analyzed in our study. Figure 2B shows the Q-Q-plot of P
alues of these SNPs, excluding SNPs from the MHC
egion. We found 2 SNPs, rs2476601 and rs6679677, in
trong LD with each other, to be associated with AC-DILI
for rs2476601, P  1.3  104, OR, 2.1; 95% CI: 1.5–3.2)
Supplementary Table 2). Rs2476601 is a nonsynonymous
NP in PTPN22, the gene encoding the lymphoid-specific
rotein tyrosine phosphatase, nonreceptor type 22 in-
olved in T cell-receptor signaling, and has been reported
o be associated with multiple autoimmune diseases.28
Although the association was not genome-wide signifi-
cant, it had a P value of .023 after Bonferroni correction
or all the published GWA associations with autoimmune
iseases that were genotyped in our study.27 The associa-
ion of the PTPN22 SNPs with DILI appeared stronger in
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342 LUCENA ET AL GASTROENTEROLOGY Vol. 141, No. 1Figure 1. AC-DILI genome-wide association
results. Each point represents association
analysis results for a single SNP with chromo-
some position on the x-axis and log10 P
value on the y-axis. All 201 DILI cases and 532
population controls were included in the anal-
ysis. SNPs with P values smaller than 106
and 107 are highlighted in green and red,
respectively. Panel A shows the results for the
entire genome. Panels B–D show enlarged
sections of the MHC region. Panel B is an en-
largement of the results presented in A, panel
C shows the analysis of each SNP in this chro-
mosome region conditioned on the top class II
SNP (rs9274407), and panel D shows analysis
of each SNP conditioned on the top class I and
II SNPs (rs9274407 and rs2523822). Positions
of a range of MHC genes are shown in B–D.
-
o
r
a
c
3
N
D
r
r
S
w
D
b
t
s
t
a
D
D
i
a
c
r
a
E
(
g
c
O
C
s
t
1
i
r
r
r
B
A
SI
C
A
N
D
TR
A
N
SL
A
TI
O
N
A
L
LI
V
ER
July 2011 HLA AND AMOXICILLIN-CLAVULANATE TOXICITY 343the UK and US cases than in those from Spain (Supple-
mentary Table 2).
HLA Analysis
To investigate further the observed associations
within the MHC, high-resolution genotyping of HLA-A,
B, -DRB1, -DQA1, and -DQB1 was performed on a subset
f 177 cases and 219 genetically matched controls. The
elationship between HLA genotypes and the top associ-
ted SNPs within Northwestern European and Spanish
ases and controls was investigated (Supplementary Table
). There were substantial differences in LD between
orthwestern Europeans and Spanish for rs9274407 and
QB1*0602 and for rs2523822 and A*0201 that were
eflected in subsequent associations. In particular,
s2523822/C showed poor correlation with A*0201 in
panish, especially among cases (r2  0.64) compared
ith Northwestern Europeans (r2  0.96 for cases) (Sup-
plementary Table 3). DQB1*0602 was the most signifi-
cantly associated HLA allele with DILI overall (P  1.4 
106, OR, 3.3; 95% CI: 2.0–5.7) and within each group.
RB1*1501 was in near-perfect LD with DQB1*0602 in
oth Northwestern European and Spanish cases and con-
rols, and the association of either allele with AC-DILI was
tatistically similar. A summary of key findings condi-
ioned on DQB1*0602 is provided in Table 4. DQA1*0102,
n allele included in but not exclusive to the DRB1*1501-
QB1*0602 haplotype, was slightly more significant than
QB1*0602 in Northwestern Europeans but not in Span-
sh. Conditioned on DQB1*0602, DQB1*0402 was associ-
ted in Northwestern Europeans with nominal signifi-
ance, but not in Spanish. This is consistent with the SNP
esults, where rs9274407 conditioned on rs3135388 was
n indicator of a DQB1*0402 association in Northwestern
uropeans (Supplementary Table 3). Unlike its tag SNP
rs3135388), DQB1*0602 was associated in the Spanish
roup conditioned on rs9274407 with nominal signifi-
ance (P  .01).
The class I allele A*0201 was associated (P  2  106,
R, 2.2; 95% CI: 1.6–3.2) with DILI in the combined cases.
onsistent with the SNP results, there was a significant
tatistical interaction between A*0201 and DQB1*0602 in
he combined cases (P  .0048, OR, 3.3; 95% CI: 1.4–7.7)
together with the UK and US cases individually (P .012,
OR, 3.9; 95% CI 1.4–11 and P  .03, OR, 5.4; 95% CI:
.2–25). However, A*0201 was not as strongly associated
Table 2. Summary of Top Associated SNPs From the Genome
SNPs HLA allele tagged
HLA
class Chr
Position
(build 36)
rs9274407 II 6 32740809 4
s9267992 II 6 32328375 6
s3135388 DRB1*1501-DQB1*0602 II 6 32521029 3
s2523822 HLA-A*0201 I 6 29936639 1
NOTE. The data shown are for all 201 drug-induced liver injury cases
Chr, chromosome; N/A, not applicable.n Spanish as in Northwestern Europeans. A test of het-Figure 2. Additional Q-Q plots for ADME and autoimmune genes.
Panel A shows a Q-Q plot for ADME genes and panel B a Q-Q plot for
GWAS hits for autoimmune disease genes. The autoimmune disease
SNPs studied related to type 1 diabetes, Crohn’s disease, celiac dis-
ease, systemic lupus erythematosus, ankylosing spondylitis, primary
biliary cirrhosis, systemic sclerosis, juvenile arthritis, and Grave’s dis-
ease. All show an association with at least 1 of these diseases with P -Wide Analysis Together With Conditioning Analysis
P value OR (95% CI)
P value conditioned
on rs9274407
P value conditioned
on rs3135388
.8  1014 3.1 (2.34.2) N/A .00011
.8  1013 3.1 (2.34.2) .07 .0034
.5  1011 2.8 (2.13.8) .93 N/A
.8  1010 2.3 (1.82.9) 1.2  109 2.1  1010
and 532 controls.5  108.27
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344 LUCENA ET AL GASTROENTEROLOGY Vol. 141, No. 1erogeneity on the effect of A*0201 gave a P value of .071,
suggesting a population-dependent effect (Supplementary
Figure 4). This inconsistency with the result of rs2523822
could be explained by the much lower LD between
rs2523822 and A*0201 in Spanish cases (Supplementary
Table 3). Additionally, B*1801 was associated in Spanish
cases with nominal significance independently of A*0201
and DQB1*0602 but not in Northwestern Europeans.
The frequencies of the 5-gene HLA haplotypes in cases
and controls are shown in Supplementary Table 4. The
most significant association was observed for A*0201-
B*0702-DRB1*1501-DQB1*0602 in Northwestern Europe-
ans (P  .00074; OR, 13) and Spanish (P  .013; OR, 20).
However, both DQB1*0602 and A*0201 were significantly
associated conditioned on that haplotype. A*0201-B*1801
was significantly associated (P .015; OR, 6.4) in Spanish
only.
Relationship of Genotype With Clinical
Features
We investigated the relationship between the top
associated HLA alleles and clinical features of AC-DILI,
including age at onset, pattern of liver damage, and dis-
ease severity as assessed by magnitude of transaminase or
bilirubin elevation (Supplementary Table 5). B*1801 car-
iage was significantly correlated with peak ALT values in
panish (P  .0056, Figure 3A) but not in Northwestern
uropeans (P  .90). We further investigated whether the
ffect of B*1801 varied in Spanish cases according to
attern of liver damage (Figure 3B). The estimated effect
n hepatocellular cases (OR, 8) was much larger than
holestatic/mixed cases (OR, 2), but the apparent hetero-
eneity was not statistically significant (P .10). No other
otable correlations were observed in either Spanish or
orthwestern Europeans.
Clinical Predictive Values
Assuming the prevalence of AC-DILI is 0.014%,2
the best positive predictive value is 0.1% for Northwestern
Europeans based on the presence of both A*0201 and
QB1*0602 (frequency of 41% in cases) and 0.13% for
panish based on the presence of both B*1801 and
QB1*0602 (frequency of 8.5% in cases). In each case,
hese alleles are present at approximately 10-fold higher
ates than in the population overall. The best negative
redictive value (NPV), expressed for clarity as 1-NPV, is
.006% for Northwestern Europeans based on the absence
f A*0201 (carriage frequency 74% in cases) and 0.007%
for Spanish based on the absence of rs2523822/C (car-
riage frequency 74% in cases), approximately half the
assumed rate of AC-DILI in the population overall (Sup-
plementary Table 6).
Discussion
This study was accomplished through an interna-
tional cooperation to assemble a considerably larger and
more diverse AC-DILI patient collection than previousTa T
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July 2011 HLA AND AMOXICILLIN-CLAVULANATE TOXICITY 345published studies on the subject.11–13 This resulted in the
most powerful and comprehensive investigation into ge-
netic risk factors for AC-DILI and the largest GWA for any
rare serious adverse event conducted to date. We con-
Figure 3. Relationship between HLA genotype and clinical parameters.
Panel A shows the relationship between HLA-B*1801 and peak ALT in
panish cases and panel B a comparison of odds ratios for different liver
Table 4. Analysis of Combined SNP and HLA Data by Conditio
Conditioned on
PC1  PC2  sex,
and: Allele
All
(177 cases, 219 co
OR (95% CI) P
DQB1*0602 4.2 (2.76.6) 4.6
 DQB1*0602 DRB1*1501 0.8 (0.15)
 DQB1*0602 DQA1*0102 2.0 (1.24.2)
DQB1*0602 DQB1*0402 2.3 (0.96)
DQB1*0602 A*0201 2.2 (1.63.2) 1.9
DQB1*0602 B*1801 2.0 (1.03.9)
DQB1*0602 and A*0201 rs2523822/C 3.9 (1.511)
 DQB1*0602 and A*0201 rs9274407/Minor 2.4 (0.945.9)
rs9274407/Minor DQB1*0602 1.8 (0.685.0)
C, principal component.amage patterns for HLA-B*1801 in Spanish cases and controls.firmed the previous associations of HLA-DRB1*1501 and
DQB1*0602 with DILI susceptibility, and our larger sam-
ple size and GWA approach allowed the identification of
additional HLA risk factors together with an apparent
statistical interaction between 2 HLA alleles.
In particular, a novel contribution to disease suscepti-
bility from a common variant (rs2523822) in the region of
the HLA-A locus was found. This variant is a tag for the
HLA-A*0201 allele in individuals of European ancestry,25
and the effect of rs2523822 and A*0201 were indistin-
guishable in the Northwestern European subset of this
study. When considered as an individual risk factor, the
effect of A*0201 was seen only in cases of Northwestern
European, and not Spanish, origin. This is in spite of the
most strongly associated SNP in this region (rs2523822)
showing an effect of similar magnitude in both popula-
tions. Nevertheless, the OR for A*0201 in the Spanish
subset was also in the same direction as for the other
subjects. Comparison of the LD patterns in Northwestern
vs Southern European subsets showed that rs2523822 is
indeed strongly correlated with A*0201 in Northwestern
Europeans (r2  0.96) but not in Spanish (r2  0.64).
Given this observation, and the high degree of functional
variation in the MHC region, one plausible explanation is
that A*0201 is not the actual causal variant underlying the
association with rs2523822 but merely happens to be an
adequate “tag” for the causal site(s) in Northwestern Eu-
ropeans but not in the Spanish. Similarly, because the
most significant class II association in Northwestern Eu-
ropeans rs9274407 was still significantly associated con-
ditioned on HLA-DRB1*1501-DQB1*0602 (or its tag SNP
rs3135388) but the opposite was not true: there is a
possibility that the causal variant(s) may lie in another
class II locus. Further investigation of genetic variation in
the MHC region and functional assessment of these vari-
ants in the context of AC-DILI will be necessary to identify
the causal site(s) securely. The differences among popula-
tions in terms of risk associated with class I HLA alleles
are somewhat similar to the situation with serious skin
rash induced by antiepileptic drugs in East Asians where
HLA-B*1502 is a risk factor in Han Chinese but not in
other groups such as Japanese.29 The complexity of the
g on DQB1*0602
ls)
Northwestern European
(130 cases, 107 controls)
Spanish
(47 cases, 121 controls)
lue OR (95% CI) P value OR (95% CI) P value
010 3.3 (2.0–5.7) 1.4  106 7.4 (3.117.8) 7.4  106
1.4 (0.210) .77 N/A .26
2.9 (1.17.2) .02 1.8 (0.75) .37
7.5 (1.538) 4.9  103 0.9 (0.16) .4
106 2.9 (1.84.4) 7.9  107 1.6 (0.882.8) .13
0.98 (0.362.6) .95 4.0 (1.511) .004
0.86 (0.154.9) .86 7.9 (2.130) .004
9.7 (1.949) 1 103 0.67 (0.114.1) .65
0.37 (0.0711.9) .2 11 (1.685) .01nin
ntro
va
 1
.72
.02
.1

.05
.01
.07
.23MHC region in terms of the number of variable sites, and
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346 LUCENA ET AL GASTROENTEROLOGY Vol. 141, No. 1local differences in LD, make definitive claims of causality
particularly difficult.
A relatively rare HLA haplotype positive for DRB1*1501
together with DQB1*0602, A*0201, and B*0702 was signif-
icantly associated with AC-DILI in both Northwestern
Europeans and Spanish. However, conditioning analysis
showed that the association was driven by the A*0201 and
the DRB1*1501-DQB1*0602 alleles regardless of the cis or
trans configuration. We found compelling evidence of a
statistical interaction between rs9274407 and rs2523822
(or DQB1*0602 and A*0201). An interaction of this nature
appears biologically plausible in view of the complemen-
tary roles for the class I and class II HLA gene products in
the T-cell response. If validated, this demonstrates the
kind of gene-by-gene interaction that has often been spec-
ulated on but rarely observed in studies of complex traits
in humans.30 On the other hand, without knowing the
rue causal variants, especially for the class I allele, we
annot exclude the possibility that the interaction be-
ween classes I and II is due to imperfect tagging of the
ausal variants by SNPs or classical HLA alleles.
We found evidence for an increased frequency of
QB1*0402 in the Northwestern European cases. This
llele is associated with increased susceptibility to the
utoimmune liver disease, primary biliary cirrhosis
PBC).31 PBC occurs predominantly in females, whereas
a majority of the DILI patients positive for DQB1*0402 in
his study were males and therefore unlikely to be misdi-
gnosed PBC cases. Xenobiotic exposure is believed to
ave a role in triggering PBC,32 and it is possible that
here are common susceptibilities to PBC and AC-DILI.
From previous reports, it appears that the HLA class II
RB1*1501-DQB1*0602 haplotype is also a risk factor for
ther forms of DILI.14,33 A second HLA class II haplotype,
RB1*0701-DQA1*0201, is a risk factor for hepatotoxicity
elating to ximelagatran34 and lapatinib.35 However, apart
rom our reported association between flucloxacillin DILI
nd B*570116 and an association between A*3303 and
ticlopidine DILI in Japanese,36 the role of HLA class I
genotypes in susceptibility to DILI generally is still poorly
understood and merits further investigation. Interest-
ingly, in addition to being possibly associated with DILI
in the Spanish, B*1801 was further associated with peak
ALT values in these cases, suggesting a possible role for
this allele in phenotypic expression. It is worth noting
that the only 2 cases of fulminant liver failure in the
Spanish cohort were both B*1801 carriers.
Additionally, the possibility that the genetic determi-
nants of DILI risk detected here using common SNP
markers may potentially represent contributions from a
larger number of rare genetic variants should be consid-
ered.37 This is particularly relevant to rare adverse events
uch as DILI, for which rare genetic determinants are in
rinciple one of the most parsimonious explanations.
etection of rare variants will require whole genome se-
uencing, which is increasingly feasible.38
Although our GWA study failed to provide any ge-
nome-wide significant evidence of a role for non-HLAgenes, including ADME genes, in AC-DILI susceptibility,
it remains possible that other genes contribute with
smaller effects. In particular, the connection between AC-
DILI and autoimmune disease is further extended by the
association of the PTPN22 SNP rs2476601. This associa-
tion could also apply to autoimmune-related DILI be-
cause of other drugs because the gene product has a
general role in regulation of T-cell responses.
This unique study has demonstrated the ability to de-
termine novel genetic risk factors of AC-DILI in diverse
populations. We have shown there are improvements in
the NPV for the combined HLA risk genotypes compared
with our assumed incidence of AC-DILI of 0.014% with
carriers of both class I and II risk alleles showing a nearly
10-fold increase in risk. A positive predictive value of just
0.1% means that HLA genotyping will not be an effective
means of prospectively identifying those at risk of AC-
DILI, but our findings have clinical utility in that HLA
genotyping may be of value in strengthening AC-DILI
diagnoses in view of the high NPVs seen.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2011.04.001.
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